Economic evaluations of health technologies for cancer are frequently seen in the literature, but not all economic perspectives have the same frequency [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857326 | PMC |
| http://dx.doi.org/10.3390/curroncol30010018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How and why funders support engaged research.
Proc Natl Acad Sci U S A
January 2025
Ewing Marion Kauffman Foundation, Kansas City, MO 64110.
Research that better aligns policy, practice, and research communities is gaining momentum around the world. This includes engaged research strategies that bring partners, and their diverse perspectives and kinds of knowledge, together to shape research agendas with on-the-ground-needs and to create dynamic problem-solving processes. These approaches aim to generate more equitable and effective solutions to societal challenges.
View Article and Find Full Text PDFThe Paradigm Shift From Patient to Health Consumer: 20 Years of Value Assessment in Health.
J Med Internet Res
January 2025
Virginia Commonwealth University, Richmond, VA, United States.
Health care is undergoing a "revolution," where patients are becoming consumers and armed with apps, consumer review scores, and, in some countries, high out-of-pocket costs. Although economic analyses and health technology assessment (HTA) have come a long way in their evaluation of the clinical, economic, ethical, legal, and societal perspectives that may be impacted by new technologies and procedures, these approaches do not reflect underlying patient preferences that may be important in the assessment of "value" in the current value-based health care transition. The major challenges that come with the transformation to a value-based health care system lead to questions such as "How are economic analyses, often the basis for policy and reimbursement decisions, going to switch from a societal to an individual perspective?" and "How do we then assess (economic) value, considering individual preference heterogeneity, as well as varying heuristics and decision rules?" These challenges, related to including the individual perspective in cost-effectiveness analysis (CEA), have been widely debated.
View Article and Find Full Text PDFGuidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World.
Clin Pharmacol Ther
January 2025
Boston Consulting Group, Zurich, Switzerland.
The value of a medicine is defined by its impact on patients, caregivers, health system, and society. A pharmaceutical company will generate evidence to demonstrate this value in various studies, including randomized clinical trials, non-interventional and observational studies, real-world data analyses, modeling, and simulation. The quality and strength of the evidence supporting a medicine's effectiveness, safety and product quality will drive decisions by healthcare system stakeholders for marketing authorization (regulatory authorities).
View Article and Find Full Text PDFCan medical comorbidities modify the clinical evolution of mild cognitive impairment and Alzheimer’s dementia?
Alzheimers Dement
December 2024
Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
Background: Despite the health and societal burden that Alzheimer’s disease (AD) has on the elderly population, the underlying cause is not fully understood. Researchers are investigating possible mechanisms, and current studies have suggested that a number of comorbidities increase/decrease the likelihood of AD onset. The aim of the current study was to explore the associations between various comorbidities and AD in older Australians from an epidemiological perspective.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!